Get the Stockscreener App
7.9017
5.47%
0.5017
Promis Neurosciences Inc stock is traded at $7.9017, with a volume of 25,050.
It is up +5.47% in the last 24 hours and down -1.27% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$7.40
Open:
$7.43
24h Volume:
25,050
Relative Volume:
0.83
Market Cap:
$16.80M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-39.59
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
+11.66%
1M Performance:
-1.27%
6M Performance:
-27.78%
1Y Performance:
-72.00%
1-Day Range:
$7.43
$8.04
1-Week Range:
$6.62
$8.04
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
7.805 | 15.93M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.85 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.46 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.59 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.74 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences regains Nasdaq compliance - MSN
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Guidance Update: Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansionWeekly Profit Summary & Community Consensus Trade Signals - Улправда
Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansion2025 Volatility Report & Daily Entry Point Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. (23J0) stock could outperform next yearQuarterly Trade Summary & Consistent Profit Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. stock appeals to dividend seekers2025 Volume Leaders & Fast Momentum Stock Entry Tips - DonanımHaber
Why ProMIS Neurosciences Inc. stock remains on watchlistsGold Moves & Safe Capital Growth Plans - DonanımHaber
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial By Investing.com - Investing.com South Africa
ProMIS Neurosciences (PMN) Completes Patient Enrollment for Alzh - GuruFocus
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial - Investing.com
ProMIS Neurosciences exceeds target enrollment in Precise-AD phase 1b clinical trial - marketscreener.com
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease - The Manila Times
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 ... - Caledonian Record
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule - Investing.com Australia
ProMIS Neurosciences Regains Nasdaq Compliance - TipRanks
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
ProMIS Neurosciences Announces Third Quarter 2019 Results - PR Newswire
ProMIS Neurosciences announces publication highlighting PMN310 - MSN
Cash per share of ProMIS Neurosciences Inc. – DUS:23J - TradingView — Track All Markets
ProMIS Neurosciences shareholders approve share consolidation proposal By Investing.com - Investing.com Nigeria
ProMIS Neurosciences shareholders approve share consolidation proposal - Investing.com
ProMIS Neurosciences (PMN) Reveals Promising Study Results for A - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - The Manila Times
ProMIS Neurosciences Announces New Peer-Reviewed - GlobeNewswire
Fortrea (NASDAQ:FTRE) & Promis Neurosciences (NASDAQ:PMN) Head-To-Head Review - Defense World
ProMIS Neurosciences: Buy Rating Backed by Innovative EpiSelect™ Platform and Promising PMN310 Candidate - TipRanks
Pretax income of ProMIS Neurosciences Inc. – BER:23J - TradingView
ProMIS Neurosciences (PMN) Price Target Increased by 2,288.89% to 137.06 - Nasdaq
Can ProMIS Neurosciences Inc. (23J0) stock sustain margin levelsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
HC Wainwright Has Strong Forecast for PMN FY2025 Earnings - Defense World
How strong is ProMIS Neurosciences Inc. (23J0) stock earnings growth2025 Institutional Moves & Weekly Breakout Watchlists - Newser
How geopolitical risks impact ProMIS Neurosciences Inc. (23J0) stock2025 Market Trends & Long-Term Growth Stock Strategies - Newser
ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s - MSN
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
Why hedge funds are buying ProMIS Neurosciences Inc. stockWeekly Trade Recap & AI Based Buy/Sell Signal Reports - Newser
symbol__ Stock Quote Price and Forecast - CNN
ProMIS Neurosciences stock rises after promising Alzheimer’s research data By Investing.com - Investing.com Australia
HC Wainwright & Co. Maintains ProMIS Neurosciences (PMN) Buy Recommendation - Nasdaq
ProMIS Neurosciences Inc (23J0.DU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
PMN: HC Wainwright & Co. Raises Price Target and Maintains Buy R - GuruFocus
ProMIS Neurosciences (PMN) Sees Revised Price Target from H.C. W - GuruFocus
ProMIS Neurosciences stock rises after promising Alzheimer’s research data - Investing.com
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Promis Neurosciences Inc Stock (PMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cashman Neil | Chief Scientific Officer |
Feb 10 '25 |
Buy |
0.97 |
15,000 |
14,595 |
16,617 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):